Pericarditis Global Market Report 2024

The pericarditis market size has grown strongly in recent years. It will grow from $2.17 billion in 2023 to $2.35 billion in 2024 at a compound annual growth rate (CAGR) of 8.4%. The growth observed in the historical period can be attributed to several factors, including the increased prevalence of cardiovascular diseases, an aging population with higher disease risks, improved understanding of disease pathophysiology, globalization of healthcare services, and ongoing drug development and innovation.

The pericarditis market size is expected to see strong growth in the next few years. It will grow to $3.2 billion in 2028 at a compound annual growth rate (CAGR) of 8.1%. The anticipated growth in the forecast period can be attributed to increased attention on precision medicine, regulatory support for orphan drugs, the influence of patient advocacy and support groups, expanding research on inflammatory pathways, and global efforts aimed at cardiovascular disease prevention. Major trends expected in the forecast period include advances in diagnostic technologies, the integration of artificial intelligence in diagnostics, improved management strategies for recurrent pericarditis, the incorporation of telemedicine in follow-up care, a focus on patient education and support, and enhancements in imaging technologies.

The anticipated rise in cardiovascular diseases is set to drive the growth of the pericarditis market. Cardiovascular diseases encompass various conditions affecting the heart or blood vessels, often associated with the accumulation of fatty deposits in arteries and an elevated risk of blood clotting. The prevalence of pericarditis, a condition that can lead to severe cardiovascular complications or even death if left untreated, is closely tied to the increasing rates of cardiovascular diseases. In the United States, an article from the Centers for Disease Control and Prevention (CDC) in October 2022 reported that a heart attack occurs every 40 seconds, with approximately 805,000 Americans experiencing a heart attack annually. The rising incidence of cardiovascular diseases, attributed to factors such as smoking, high blood pressure, and high cholesterol, is a driving force behind the pericarditis devices market's growth.

The growth in healthcare spending is expected to provide a significant boost to the pericarditis market. Healthcare spending, representing the financial resources allocated for various healthcare services and activities, supports the comprehensive management of pericarditis - from research and diagnosis to treatment and patient education. According to the 2021-2030 National Health Expenditure (NHE) report by the Centers for Medicare & Medicaid Services in March 2022, national health spending is projected to increase by an average of 5.1% annually between 2021 and 2030, reaching nearly $6.8 trillion. This increase in healthcare spending creates a conducive environment for addressing pericarditis, ensuring advancements in research, diagnosis, and treatment. Notably, the projected rise in Medicare and Medicaid spending further contributes to the overall growth of the pericarditis market.

Leading companies in the pericarditis market are focusing on innovation, introducing products such as valves for pericardial tissues to cater to broader customer bases and drive revenue growth. Valves for pericardial tissues are designed for use in cardiac surgery, particularly in procedures involving heart valve replacement or repair. Edwards Lifesciences, a US-based technology company, launched the SAPIEN 3 Ultra RESILIA valve in September 2022. This innovative valve integrates advanced anti-calcification technology, addressing a crucial factor contributing to the need for reintervention following heart valve replacement. The introduction of such products reflects a commitment to innovation, meeting the evolving needs of patients and enhancing their overall health and longevity.

Innovative products, such as therapies for recurrent pericarditis, are being developed by major companies in the pericarditis market to cater to a wider audience and boost revenue. Therapies for recurrent pericarditis involve medical interventions and treatment strategies aimed at managing and preventing the recurrence of pericardium inflammation. Kiniksa Pharmaceuticals Ltd., a Bermuda-based biotechnology company, received FDA approval for ARCALYST in March 2021. ARCALYST is a subcutaneously-injected recombinant fusion protein designed to obstruct interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) signaling. Specifically developed for treating recurrent pericarditis, ARCALYST demonstrated significant improvements in clinical trials, addressing an unmet medical need in the management of recurrent pericarditis.

In March 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, acquired Arena Pharmaceuticals for USD 6.7 million. This acquisition positions Pfizer to expand its portfolio with diverse and developmental-stage therapeutic candidates in the inflammation and immunology therapeutic areas. Arena Pharmaceuticals, a US-based biopharmaceutical company, is actively developing potential therapies for immuno-inflammatory diseases, including innovative medications undergoing extensive testing for various disorders.

Major companies operating in the pericarditis market report are Pfizer Inc., AstraZeneca plc, Allergan plc, Merck & Co. Inc., Bayer AG, Reckitt Benckiser Group plc, PerkinElmer Inc., Novartis International AG, Sanofi S.A., Johnson & Johnson Services Inc., Takeda Pharmaceutical Co. Ltd., Zydus Cadila Healthcare Ltd., Sun Pharmaceutical Ltd., Regeneron Pharmaceuticals Inc., Kiniksa Pharmaceuticals Ltd., R-Pharm International LLC, Unimed Laboratories, Teva Pharmaceutical Industries Ltd., Swedish Orphan Biovitrum AB, Cigna Group, Hikma pharmaceutical plc, Wockhardt Ltd., XYMAS Pharmaceutical, Sakura Finetek USA Inc., Hitachi High-Technologies Corporation, Leica Biosystems Nussloch GmbH, Euromex Microscopen BV, Celestron LLC, Labomed Inc., Olympus Corporation, Bruker Corporation.

North America was the largest region in the pericarditis market in 2023. Asia-Pacific is expected to be the fastest-growing region in the pericarditis market report during the forecast period. The regions covered in the pericarditis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pericarditis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

There are three major types of pericarditis, acute pericarditis, chronic pericarditis, and recurrent pericarditis. Acute pericarditis involves a sudden and painful inflammation in the pericardium surrounding the heart. Diagnosis and treatment of pericarditis involve various methods, including electrocardiogram (ECG), echocardiogram, computerized tomography (CT), X-ray, medication, and, in some cases, surgical intervention. The treatment of pericarditis is applied in different healthcare settings, such as hospitals, clinics, medical institutes, ambulatory surgical centers, and research organizations.

The pericarditis market research report is one of a series of new reports that provides pericarditis market statistics, including pericarditis industry global market size, regional shares, competitors with a pericarditis market share, detailed pericarditis market segments, market trends and opportunities, and any further data you may need to thrive in the pericarditis industry. This pericarditis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.